Overview

Gender

male

Dr. Multani brings to ORIC more than 20 years of experience in oncology drug development and treatment of patients with cancer. Most recently, Dr. Multani served as Chief Medical Officer of Ignyta, which was acquired by Roche, where he led all development and regulatory activities related to multiple clinical stage assets, including Ignyta’s lead program entrectinib, which is currently approved in the United States and Japan.

Prior to Ignyta, Dr. Multani was Chief Medical Officer of Fate Therapeutics, and prior to that he held multiple leadership positions at Kalypsys, Kanisa and Salmedix. Dr. Multani started his biotech career at Biogen Idec, where he was involved with the development of both Zevalin® and Rituxan® for treatment of non-Hodgkin lymphoma.

Prior to his career in biotech, Dr. Multani held academic and clinical positions at Harvard Medical School and at Massachusetts General Hospital. His postdoctoral training included a fellowship in hematology and oncology at Dana-Farber/Partners and an internship and residency in internal medicine at Massachusetts General Hospital. Dr. Multani received an MD from Harvard Medical School and an MS in clinical epidemiology from Harvard School of Public Health. He currently serves on the board of directors of Erasca and Chimerix (NASDAQ: CMRX).